



First-in-Class
Bispecific Antibodies
For Cancer
Immunotherapy

Jane Dancer,
CBO

4 June 2018



F-star Overview

Management Team



John Haurum, MD DPhil, CEO
Ex-ImClone Systems/Eli Lilly
Founder and CSO of Symphogen A/S



Jane Dancer, PhD MBA, CBO
Ex-AstraZeneca/CAT
VP BD at Cellzome



Tolga Hassan, BA FCA, CFO
Ex-Finance & Corp. Development,
Johnson Matthey and Andersen



Neil Brewis, PhD DSc, CSO
Ex-GSK Head of Biopharm Research
Head of Research, Domantis

Investors



\$200m

Raised in
non-dilutive capital
and revenues



90 employees
75 working in R&D

Partners



Advantages of Bispecific Antibodies over Combinations



Superior, clinically relevant potency through novel mechanistic biology

- Directing antibodies to disease-specific targets or tissue
- Co-mobilising immune system components for greater efficacy
- Crosslinking of cell-surface receptors


Improved safety profile

Directing antibodies to local targets may reduce systemic side effects

Controlling price

A bispecific antibody offers price benefits over combinations

A Powerful Approach to Creating Bispecific Antibodies



Permissive CH3 domain
loop residues identified

Limited number
of amino acid substitutions


Fc region with
antigen binding

Effector functions
retained

Plug-and-play insertion
of Fcab into any mAb

Virtually limitless
possibilities

Significant Proprietary and Partnered Pipeline



◆ Candidate Selection ★ IND Filing